{"entity":{"id":"hookipa-pharma","kind":"company","name":"Hookipa Pharma","aka":["HOOKIPA Pharma Inc.","Hookipa Biotech","NASDAQ:HOOK"],"tldr":"Hookipa Pharma is a Vienna biotech that engineers arenaviruses into vaccines that drive unusually strong killer T-cell responses; HB-200 targets the HPV16 proteins that cause many head and neck cancers.","summary":"Hookipa Pharma develops arenavirus-based immunotherapies built on lymphocytic choriomeningitis virus and Pichinde virus vectors, which infect dendritic cells and induce large populations of antigen-specific CD8 T cells. HB-200 (eseba-vec) alternates the two vectors, each encoding an HPV16 E7/E6 fusion protein, and has been studied with pembrolizumab in first-line HPV16-positive head and neck cancer. Its KRAS programme HB-700 was licensed to Roche and later returned. The company announced a strategic restructuring in 2025.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.hookipapharma.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["hb-200"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Vienna","country":"AT","companyType":"biotech","website":"https://www.hookipapharma.com/","ticker":"NASDAQ:HOOK","founded":2011,"stage":"public","investors":[],"funding":[]},"route":"/companies/hookipa-pharma/","neighbours":{"drug":[{"id":"hb-200","kind":"drug","name":"HB-200","route":"/drugs/hb-200/"}]}}